Melanotan II: mechanism, evidence and research limits

Melanotan II (MT-II) is a synthetic, lactam-bridged cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone (alpha-MSH). It is a pharmacologically active peptide and non-selective melanocortin receptor agonist, not a topical cosmetic ingredient, an endogenous hormone, or a validated multi-ingredient blend. It entered small early human studies and remains a research substance with limited human evidence; it is not an approved therapeutic formulation in Australia. A vial or nasal spray sold online under this name is an unapproved commercial product, not an approved medicine label or a substitute for the historical study material.

Melanotan II is a synthetic cyclic peptide that activates melanocortin signalling. Small, early controlled human studies found pigmentary and acute erectile-response signals, while animal work explored energy balance. Those findings do not establish a consumer tanning, weight-loss, or sexual-health treatment. Australia has no approved Melanotan II product, and TGA testing has found inconsistent amounts in seized online tanning products.

Melanotan II is genuinely a peptide: the phase I report describes a cyclic seven-residue analogue of alpha-MSH, joined by a lactam bridge. Alpha-MSH is part of the melanocortin signalling system; MT-II is a synthetic analogue rather than a hormone produced by the body. The human erectile-dysfunction literature calls it a non-selective melanocortin receptor agonist. That broad activity matters because a single compound can produce effects beyond skin pigmentation. [1] [3]

The most accurate category is a historical investigational human candidate and research tool with preclinical uses, not an approved Australian medicine. It is not a topical tanning ingredient or a validated mixture. Product names such as “melanotan” can obscure that distinction: a substance name describes a molecule, whereas an approved formulation has an assessed manufacturer, strength, quality controls, indication and product information. The TGA states that no product containing Melanotan II is in the ARTG or approved for supply in Australia. [7] [9]

MT-II was designed as an alpha-MSH analogue with strong melanotropic activity in vitro, and the clinical reports describe it as a melanocortin receptor agonist. In people, the small studies demonstrate outcomes after exposure; they do not identify which individual receptor subtype caused each outcome in each participant. It would therefore be misleading to present a receptor-by-receptor human pathway as settled, or to imply that a pigmentary effect proves a defined benefit in another organ system. [1] [3]

In the small phase I study, increased pigmentation was measured after MT-II exposure in two of three healthy male volunteers. That is an observed pharmacological signal, not evidence that an induced tan prevents ultraviolet injury. The TGA explicitly warns that no tan, real or artificial, protects skin from sun damage in the way suitable sunscreen does. [1] [6]

The pivotal pigmentation paper was a pilot phase I experiment in three normal male volunteers. It used a single-blind, alternating saline-versus-MT-II design; two participants had increased pigmentation of the face, upper body and buttock, assessed by reflectance and visual observation one week after dosing ended. Mild nausea was reported at most MT-II dose levels, and one participant experienced somnolence and fatigue at the highest study exposure. [1]

This study supports only a limited conclusion: under monitored research conditions, MT-II produced a pigmentary signal in a tiny sample. It was not a long-term skin-cancer study, a sun-protection study, or a quality assessment of retail sprays or vials. Its size, all-male sample and short follow-up make it unsuitable for estimating durable benefit or uncommon harms. [1] [6] [7]

A double-blind, placebo-controlled crossover trial enrolled 10 men with psychogenic erectile dysfunction. During six-hour RigiScan monitoring, clinically apparent erections occurred in 8 of 10 men after MT-II; mean time with tip rigidity above 80% was 38.0 minutes with MT-II and 3.0 minutes with placebo. Nausea, stretching/yawning and reduced appetite were reported more often after MT-II. [2]

A second double-blind, placebo-controlled crossover study enrolled 10 men with erectile dysfunction and organic risk factors. Subjectively reported erections followed 12 of 19 MT-II administrations versus 1 of 21 placebo administrations; mean time with tip rigidity above 80% was 45.3 versus 1.9 minutes. Nausea and stretching/yawning were more frequent with MT-II, and severe nausea followed 4 of 19 MT-II administrations. [3]

These were small, acute, closely monitored studies in men already diagnosed with erectile dysfunction. They do not establish a licensed indication, long-term safety, an effect in people without erectile dysfunction, or a consumer administration schedule. A later report combining the investigators’ experience across 20 men likewise concluded that further research was warranted rather than demonstrating routine clinical use. [2] [3] [4]

In a rodent experiment, peripheral MT-II treatment in diet-induced obese mice reduced body weight and both visceral and subcutaneous adipose tissue; the findings were replicated in diet-induced obese rats. Pair-fed control mice lost similar total body weight but retained more adipose tissue, leading the authors to suggest that reduced food intake was important while other mechanisms might also contribute. [5]

That is useful preclinical biology, not a human obesity treatment result. The model involved rodents selected for diet-induced obesity, and the paper itself highlights the complexity of interpreting weight-reducing compounds. It cannot validate online claims about body composition, establish a human benefit-risk balance, or supply a protocol for people. [5] [7]

Nausea is the clearest repeatedly documented adverse effect in the early human reports. The pilot also recorded fatigue/somnolence at a higher experimental exposure, while the erectile-dysfunction trials recorded yawning or stretching and, in the organic-risk-factor trial, severe nausea after some MT-II administrations. Small trials cannot reliably quantify infrequent, delayed or long-term harms. [1] [2] [3]

The TGA lists reports associated with melanotan-II of increased moles and freckles, kidney dysfunction and swelling of the brain. These regulator-described reports are a reason for caution and clinical assessment; they should not be rewritten as proof that MT-II caused every reported event. Separately, the TGA warns that products sold as melanotan may be toxic, poor quality or counterfeit and have not been assessed for quality, safety or efficacy. [6]

A product-quality risk exists independently of the molecule’s pharmacology. In a 2026 investigation, TGA testing of five seized nasal-spray bottles labelled “Pure Tans Triple Strength 30 MG” confirmed MT-II but estimated 22 mg to 54 mg per bottle using the labelled 20 mL volume. That wide spread means a buyer cannot infer the actual amount from the shared label alone. [7]

The current TGA safety advisory describes Melanotan II as a prescription-only medicine in Australia, but also states that it is not approved as a tanning agent and that no Melanotan II product is included in the ARTG or approved for supply. These statements are compatible: a substance can be subject to prescription-only controls without there being an approved product that consumers can lawfully obtain. The ARTG is the TGA’s public database of therapeutic goods that can be supplied in Australia unless an exemption applies. [7] [9]

The TGA says that unapproved tanning products containing melanotan are being illegally promoted and sold online, including nasal sprays and injectable or ingestible products. It also says it is illegal to advertise melanotan to the Australian public and illegal to supply tanning products containing it without a doctor’s prescription. The regulator’s 2026 advisory reports infringement action connected with alleged unlawful supply. [6] [7]

An overseas regulator record is not an Australian approval decision, but it reinforces the distinction between a compound and an authorised medicine. In an FDA enforcement notice, Melanotan II was described as a peptide marketed as an injectable tanning product and as an unapproved new drug in that enforcement context. [8]

First, identify the evidence model. A result in three healthy male volunteers, 10 men with a defined form of erectile dysfunction, or diet-induced obese rodents answers a narrow question in that model. It does not automatically transfer to a different population, a cosmetic goal, chronic use, a nasal product or a supplied vial of uncertain composition. [1] [2] [3] [5] [7]

Second, separate a study compound from an online product. The historical trials used monitored research material; the TGA found inconsistent estimated content across products carrying the same retail label. That gap is why an article should not turn study observations into universal dilution, storage, route or administration advice. There is no approved Australian product information that supplies such a consumer regimen. [1] [2] [3] [7]

Finally, keep the claim proportionate to the endpoint. Increased pigmentation in a pilot study does not equal ultraviolet protection, rodent fat changes do not equal proven human weight loss, and short monitored erectile responses do not equal an approved sexual-health treatment. The most defensible reading is that MT-II has biological activity with limited human evidence and substantial unresolved safety, quality and regulatory issues. [1] [2] [3] [5] [6] [7]

Is melanotan II an approved medicine in Australia?

No approved Melanotan II product is included in the ARTG or approved for supply in Australia, according to the TGA’s 2026 safety advisory. The TGA describes the substance as prescription-only, but that scheduling status does not create an approved retail formulation. [7] [9]

Is melanotan II actually a peptide?

Yes. It is a synthetic lactam-bridged cyclic heptapeptide analogue of alpha-MSH. It is not an endogenous hormone, topical cosmetic active or standard multi-ingredient “blend.” [1] [3]

Do the human studies establish a tanning or sun-protection treatment?

No. A three-person phase I study found increased pigmentation in two volunteers, but it did not test sun protection or long-term skin outcomes. The TGA says that no tan, real or artificial, protects against sun damage in the way suitable sunscreen does. [1] [6]

Can the historical studies be used as a personal dosing guide?

No. They were small, monitored research studies in specific populations and do not validate a general-use schedule. In Australia, there is no approved Melanotan II product information, and TGA testing found inconsistent estimated amounts in seized products bearing the same retail label. [1] [2] [3] [7]

Does rodent weight research prove that melanotan II works for human weight loss?

No. The cited body-composition findings came from diet-induced obese mice and were replicated in rats. They are preclinical observations, not human efficacy or safety evidence. [5]

The direct human evidence is old and small: one phase I pigmentation pilot enrolled 3 healthy male volunteers, and the key erectile-dysfunction crossover trials each enrolled 10 men. These records cannot reliably estimate long-term outcomes or rare adverse events. [1] [2] [3]

Pigmentation, erectile response and rodent adiposity are different endpoints in different models. None validates consumer tanning, UV protection, weight management, sexual enhancement in the general population, or a general administration schedule. [1] [2] [3] [5] [6]

The cited regulator reports of serious events are safety signals and reported associations; they do not by themselves establish individual-event causality. Conversely, small trials cannot exclude serious or delayed harms. [1] [2] [3] [6]

Retail-product evidence is especially uncertain: the TGA found varying estimated amounts across products with the same label, and no Melanotan II product is ARTG-listed or approved for supply in Australia. This record deliberately provides no dilution, storage, route or consumer-use protocol. [7] [9]

1. [1] Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Single-blind, alternating-day saline/MT-II placebo-controlled pilot phase I study in 3 normal male volunteers.
2. [2] Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study. Double-blind, placebo-controlled crossover trial in 10 men with psychogenic erectile dysfunction, using six-hour RigiScan monitoring.
3. [3] Effect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction. Double-blind, placebo-controlled crossover study in 10 men with erectile dysfunction and organic risk factors, with RigiScan and questionnaire outcomes.
4. [4] Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II. Report of double-blind placebo-controlled crossover experience in 20 men with psychogenic and organic erectile dysfunction.
5. [5] The effects of the melanocortin agonist (MT-II) on subcutaneous and visceral adipose tissue in rodents. Peripheral MT-II experiment in low-fat-fed and high-fat diet-induced obese mice, including vehicle and pair-fed controls; adipose findings replicated in diet-induced obese rats.
6. [6] Don’t risk using tanning products containing melanotan. TGA consumer safety and compliance guidance; not a clinical trial.
7. [7] Melanotan II tanning peptide products found to be inconsistently dosed. TGA investigation and laboratory testing of five seized nasal-spray bottles suspected to contain Melanotan II; not a clinical trial.
8. [8] Notice of Opportunity for Hearing (NOOH) Manookian, Edward 8/5/16. FDA administrative enforcement notice concerning marketing and shipment of Melanotan II; not a clinical study.
9. [9] Searching the Australian Register of Therapeutic Goods (ARTG). TGA explanatory guidance on the ARTG; not a clinical study.